AbbVie reports promising results from phase 1 study of ABBV-295

AbbVie Inc. (NYSE:ABBV) is included among the 13 Undervalued Dividend Aristocrats to Buy Now. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and ...
UroToday

EAU 2026: Final Analysis of the Phase 1 First-in-Human Study of an Erdafitinib Intravesical Drug-Releasing System in Patients with NMIBC Harboring Select FGFR A…

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

SCYNEXIS, Inc. (SCYX) announces first participants dosed in phase 1 trial of SCY-247 antifungal therapy

SCYNEXIS, Inc. (NASDAQ:SCYX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On February 26, 2026, SCYNEXIS, ...
Seeking Alpha

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
ALS News Today

MDA 2026: Insmed launches Phase 1 trial of INS1202 gene therapy for ALS

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.
Business Wire

OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the ...
ascopubs.org

Preliminary results from a FIH, open-label phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab.

Therapeutic activity of a new KRASG12C inhibitor JMKX001899 in brain metastases: Preclinical models of KRASG12C-mutant non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Nasdaq

Monte Rosa Therapeutics Begins Phase 1 Study of MRT-8102 for Inflammatory Conditions with Initial Results Expected in H1 2026

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.
The Manila Times

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and ...
ascopubs.org

Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications.

A multi-center, open-label phase 1/1b dose finding, safety, and pharmacokinetic study of MBRC-101, an Anth-EphA5 monomethyl auristatin (MMAE) antibody drug conjugate, in advanced refractory solid ...